Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Completed · Phase 1, Phase 2 · NCT03744468
Conditions: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
At a glance
- Research payments reported, 2025
- $402,940
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 147
About the trial
- Sponsor
- BeiGene
- Tested
- Surzebiclimab (drug), Tislelizumab (drug), Alcestobart (drug)
- Dates
- Started 2018-11-13; completion 2025-02-06
- Results posted
- Yes
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
From ClinicalTrials.gov, last updated 2026-04-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $402,940 in research payments for this study in 2025 (26 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- Ari J. Rosenberg, MD Hematology & Oncology · Chicago, IL
- Zhonglin Hao, MD, PHD Medical Oncology · Lexington, KY
- Doru Paul, MD Hematology & Oncology · New York, NY
- Siddharth H. Sheth, D.O., MPH Student in an Organized Health Care Education/Training Program · Pittsburgh, PA
- George R. Blumenschein JR., M.D. Medical Oncology · Houston, TX
- Daruka Mahadevan, MD, PHD Medical Oncology · San Antonio, TX
- John F. Deeken, MD Medical Oncology · Fairfax, VA
- Varinder Kaur, MD Medical Oncology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Uci Health-Orange, CA $130,609
- Ut MD Anderson Cancer Center $92,022
- University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center $67,736
- Inova Loudoun Hospital, VA $52,418
- Ut Health San Antonio Mays Cancer Center $29,814
- Weill Cornell Medical College $14,171
- University of Virginia Medical Center, VA $12,025
- University of Kentucky Markey Cancer Center $3,164
- The University of Chicago $982
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.